Oncologiejournaal 2022 | Niercel- en blaascarcinoom

Dr. Astrid van der Veldt en dr. Adriaan Bins nemen samen met presentator Inge Diepman het belangrijkste ASCO-nieuws door op het gebied van niercel- en blaascarcinoom. 

De volgende onderwerpen staan op het programma: 

Adjuvante behandeling van niercelcarcinoom (RCC)

• EVEREST: Everolimus for renal cancer ensuing surgical therapy—A phase III study (SWOG S0931, NCT01120249)
• Adjuvant pembrolizumab for postnephrectomy renal cell carcinoma (RCC): Expanded efficacy analyses from KEYNOTE-564

Tweede- en laterelijnsbehandeling van gemetastaseerd RCC

• CALYPSO: A three-arm randomized phase II study of durvalumab alone or with savolitinib or tremelimumab in previously treated advanced clear cell renal cancer
• Phase 1 LITESPARK-001 (MK-6482-001) study of belzutifan in advanced solid tumors: Update of the clear cell renal cell carcinoma (ccRCC) cohort with more than 3 years of total follow-up

Eerstelijnsbehandeling van gemetastaseerd RCC

• Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Analysis of progression after first subsequent therapy in KEYNOTE-426
• Impact of subsequent therapies in patients (pts) with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (LEN + PEMBRO) or sunitinib (SUN) in the CLEAR study
• Association between depth of response (DepOR) and clinical outcomes: Exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 9ER
• The relationship between health-related quality of life (HRQoL) and clinical outcomes in patients with advanced renal cell carcinoma (aRCC) in CheckMate (CM) 214

Tyrosinekinasaeremming bij gevorderd of gemetastaseerd urotheelcelcarcinoom 

• Cabozantinib (C) in combination with atezolizumab (A) in urothelial carcinoma (UC): Results from Cohorts 3, 4, 5 of the COSMIC-021 study
• A randomised, double blind, phase II clinical trial of maintenance cabozantinib following chemotherapy for metastatic urothelial carcinoma (mUC): Final analysis of the ATLANTIS cabozantinib comparison

Niet-spierinvasief blaascarcinoom

• TRUCE-02: An open label, single-arm, phase II study of tislelizumab combined with nab-paclitaxel for high-risk non-muscle-invasive urothelial bladder carcinoma

Bekijk hier het volledige overzicht van onze ASCO 2022 oncologiejournaals en interviews.